Clinical Trial: NCT05814354
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Jiangsu HengRui Medicine Co., Ltd. |
| Information Provided By: | Jiangsu HengRui Medicine Co., Ltd. |
| Last Update Posted: | 2026-08-06 |
Study Overview
Brief Summary
The aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer.
Official Title
A Randomized, Open, Parallel-controlled, Multicenter Phase III Trial of SHR-A1811 Versus Investigator Chemotherapy in HER2-low Expressing Recurrent/Metastatic Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: SHR-A1811
- Drug: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Other Study ID Numbers
- SHR-A1811-III-306
Start Date (Actual)
2023-06-30
Primary Completion Date (Actual)
2026-03-20
Study Completion Date (Estimated)
2028-06-30
Enrollment (Actual)
551
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Jiangsu HengRui Medicine Co., Ltd. |
| Information Provided By: | Jiangsu HengRui Medicine Co., Ltd. |
| Last Update Posted: | 2026-08-06 |
Study Overview
Brief Summary
The aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer.
Official Title
A Randomized, Open, Parallel-controlled, Multicenter Phase III Trial of SHR-A1811 Versus Investigator Chemotherapy in HER2-low Expressing Recurrent/Metastatic Breast Cancer
Conditions
Breast Cancer
Intervention / Treatment
- Drug: SHR-A1811
- Drug: Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Other Study ID Numbers
- SHR-A1811-III-306
Start Date (Actual)
2023-06-30
Primary Completion Date (Actual)
2026-03-20
Study Completion Date (Estimated)
2028-06-30
Enrollment (Actual)
551
Study Type
Interventional
Phase
Phase 3